Jump to main content
Jump to site search

Issue 28, 2018
Previous Article Next Article

A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy

Author affiliations

Abstract

Prostate cancer, one of the leading causes of disease and death in men all over the world, is challenging to treat. α-Enolase, a multifunctional protein, is overexpressed on human prostate carcinoma cells, and thereby it is a potential target for treatment of prostate cancer. In the current study, the pHCT74 peptide was used to construct a kind of highly targeted liposome (pHCT74-lipo) loaded with doxorubicin (pHCT74-lipo-Dox), which specifically targeted α-enolase on prostate tumour cells. Compared with liposomes without pHCT74 modification, pHCT74-lipo-Dox displayed a superior intracellular internalization with enhanced tumour cytotoxicity. In the in vivo study, pHCT74-lipo showed much higher tumour accumulation. In addition, loaded into pHCT74-lipo, doxorubicin demonstrated significantly improved anti-tumour activity on prostate tumour-bearing mice. These results suggest that the pHCT74 peptide has potential to be used in the development of a novel drug delivery system for targeted therapy against prostate cancer.

Graphical abstract: A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 Apr 2018, accepted on 11 Jun 2018 and first published on 10 Jul 2018


Article type: Paper
DOI: 10.1039/C8NR03297A
Nanoscale, 2018,10, 13673-13683

  •   Request permissions

    A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy

    L. Wang, M. Qu, S. Huang, Y. Fu, L. Yang, S. He, L. Li, Z. Zhang, Q. Lin and L. Zhang, Nanoscale, 2018, 10, 13673
    DOI: 10.1039/C8NR03297A

Search articles by author

Spotlight

Advertisements